In adults with BMI ≥27 kg/m<sup>2</sup> and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA<sub>1c</sub> level.
Where this comes from
- Record sourced from PubMed, PMID 39496170.
- Also identified by DOI 10.7326/ANNALS-24-02457-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lingvay I, Deanfield J, Kahn SE, et al; SELECT Trial Investigators. <b>Semaglutide and cardiovascular outcomes by baseline HbA<sub>1c</sub> and change in HbA<sub>1c</sub> in people with overweight or obesity but without diabetes in SELECT.</b> Diabetes Care. 2024;47:1360-1369. 38907684.